7-[3-ethyl-1-(3-morpholin-4-ylpropyl)pyrazol-4-yl]-N-(5-propan-2-ylpyridazin-3-yl)-1,5-naphthyridin-2-amine
C27H34N8O — CID 118497408
Data last refreshed: (MolForge compound catalog, from PubChem)
About 7-[3-ethyl-1-(3-morpholin-4-ylpropyl)pyrazol-4-yl]-N-(5-propan-2-ylpyridazin-3-yl)-1,5-naphthyridin-2-amine
7-[3-ethyl-1-(3-morpholin-4-ylpropyl)pyrazol-4-yl]-N-(5-propan-2-ylpyridazin-3-yl)-1,5-naphthyridin-2-amine (PubChem CID 118497408) has the molecular formula C27H34N8O and a molecular weight of 486.62 g/mol. Its IUPAC name is 7-[3-ethyl-1-(3-morpholin-4-ylpropyl)pyrazol-4-yl]-N-(5-propan-2-ylpyridazin-3-yl)-1,5-naphthyridin-2-amine.
Molecular Properties
| Compound Name | 7-[3-ethyl-1-(3-morpholin-4-ylpropyl)pyrazol-4-yl]-N-(5-propan-2-ylpyridazin-3-yl)-1,5-naphthyridin-2-amine |
|---|---|
| PubChem CID | 118497408 |
| Molecular Formula | C27H34N8O |
| Molecular Weight | 486.62 g/mol |
| Exact Mass | 486.29 |
| IUPAC Name | 7-[3-ethyl-1-(3-morpholin-4-ylpropyl)pyrazol-4-yl]-N-(5-propan-2-ylpyridazin-3-yl)-1,5-naphthyridin-2-amine |
| SMILES | CCc1nn(CCCN2CCOCC2)cc1-c1cnc2ccc(Nc3cc(C(C)C)cnn3)nc2c1 |
| InChI | InChI=1S/C27H34N8O/c1-4-23-22(18-35(33-23)9-5-8-34-10-12-36-13-11-34)21-14-25-24(28-16-21)6-7-26(30-25)31-27-15-20(19(2)3)17-29-32-27/h6-7,14-19H,4-5,8-13H2,1-3H3,(H,30,31,32) |
| InChIKey | ASTXMMRWMASRDE-UHFFFAOYSA-N |
| XLogP | 4.43 |
| TPSA | 93.88 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 486.62 |
| LogP ≤ 5 | 4.43 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118497408 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.